Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Epidermal Growth Factor Receptor 2 (HER2)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT05384119
What this trial is testing

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Tvardi Therapeutics, Incorporated 6
Large-scale testing (Phase 3)Looking for participantsNCT07207070
What this trial is testing

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd. 312
Testing effectiveness (Phase 2)Study completedNCT05549505
What this trial is testing

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Who this might be right for
Breast Cancer
Arvinas Inc. 152
Large-scale testing (Phase 3)Study completedNCT02926196
What this trial is testing

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Who this might be right for
Triple Negative Breast Neoplasms
Istituto Oncologico Veneto IRCCS 474
Testing effectiveness (Phase 2)Study completedNCT01367288
What this trial is testing

Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers

Who this might be right for
Locally Advanced Breast CancerDuctal Histologic TypeWithout Her 2 Overexpression
Hospices Civils de Lyon 53
Not applicableLooking for participantsNCT06894173
What this trial is testing

EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Who this might be right for
Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT02411656
What this trial is testing

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Who this might be right for
EdemaErythemaEstrogen Receptor Negative+6 more
M.D. Anderson Cancer Center 71
Testing effectiveness (Phase 2)Looking for participantsNCT06441890
What this trial is testing

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast Cancer
University of Illinois at Chicago 28
Testing effectiveness (Phase 2)Ended earlyNCT04789096
What this trial is testing

Tucatinib Together With Pembrolizumab and Trastuzumab

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Breast Cancer Trials, Australia and New Zealand 31
Testing effectiveness (Phase 2)Study completedNCT03530696
What this trial is testing

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast CancerBreast Cancer Stage+3 more
University of Arizona 55
Testing effectiveness (Phase 2)Study completedNCT01271920
What this trial is testing

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Who this might be right for
Advanced HER2-positive Breast Cancer
Novartis Pharmaceuticals 45
Testing effectiveness (Phase 2)Study completedNCT01989780
What this trial is testing

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Japan Breast Cancer Research Group 160
Not applicableNot Yet RecruitingNCT07593196
What this trial is testing

HER2-positive Metastatic Breast Cancer in Kazakhstan

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 240
Not applicableUnknownNCT02108561
What this trial is testing

Breast Cancer Tumor Heterogeneity

Who this might be right for
Breast Cancer
Anne Arundel Health System Research Institute 110
Testing effectiveness (Phase 2)UnknownNCT05141786
What this trial is testing

MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Who this might be right for
Non-small- Cell Lung Cancer (NSCLC)
Shanghai Miracogen Inc. 100
Testing effectiveness (Phase 2)Study completedNCT02593227
What this trial is testing

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Marker Therapeutics, Inc. 80
Large-scale testing (Phase 3)Active Not RecruitingNCT05654623
What this trial is testing

Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 624
Not applicableActive Not RecruitingNCT06735742
What this trial is testing

Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 3
Early research (Phase 1)Study completedNCT05586841
What this trial is testing

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Who this might be right for
HR+/HER2- Advanced Breast Cancer
Beijing 302 Hospital 22
Not applicableStudy completedNCT02538562
What this trial is testing

Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Hoffmann-La Roche 1,695
Next Page